Leqvio (Inclisiran) Cost vs. Alternatives: What Women Need to Know

Import from '@/components'

What Is Inclisiran and How Does It Work?

Inclisiran is a first-in-class small interfering RNA (siRNA) therapy that silences the gene inside liver cells responsible for producing PCSK9. By blocking PCSK9 production at the messenger-RNA level rather than blocking the circulating protein after it is made, inclisiran achieves a longer duration of action than monoclonal antibody alternatives. Two injections a year maintain LDL lowering around the clock.

The PCSK9 Pathway in Plain Language

Your liver constantly recycles LDL receptors to pull LDL cholesterol out of your bloodstream. PCSK9 is a protein that tags those receptors for destruction, reducing the liver's capacity to clear LDL. Statins accidentally increase PCSK9, which partially blunts their effect. Inclisiran stops the liver from making PCSK9 in the first place, so LDL receptors stay on the cell surface and keep clearing LDL from your blood.

Why siRNA Differs from Monoclonal Antibodies

Evolocumab (Repatha) and alirocumab (Praluent) are monoclonal antibodies that intercept PCSK9 after it is secreted. They work within days but clear from the body within weeks, which is why they require injections every two or four weeks. Inclisiran works upstream at the RNA level inside hepatocytes. A single dose suppresses new PCSK9 protein synthesis for approximately six months, which is why the dosing interval is twice yearly after the initial loading doses on Day 1 and Day 90.

The ORION Trial Program

The key evidence for inclisiran comes from two Phase 3 trials published in the New England Journal of Medicine in 2020. ORION-10 enrolled 1,561 patients with established ASCVD; ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents including familial hypercholesterolemia. Both trials ran for 18 months. Inclisiran reduced LDL-C by approximately 50 percent from baseline at Day 510, a reduction that was sustained and not materially different from the reduction seen at Day 90. The FDA approved inclisiran in December 2021 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and maximally tolerated statin therapy.

How Inclisiran Compares to Alternatives: Mechanism by Mechanism

Choosing between lipid-lowering options is not simply a cost question. Mechanism, dosing burden, side-effect profile, and life-stage considerations all interact.

Inclisiran vs. Evolocumab and Alirocumab

All three drugs target the PCSK9 pathway. The practical difference is frequency and the type of molecule.

| Drug | Mechanism | Injection frequency | Approximate LDL reduction | |---|---|---|---| | Inclisiran (Leqvio) | siRNA (stops PCSK9 production) | Twice yearly | ~50% | | Evolocumab (Repatha) | Monoclonal antibody (blocks PCSK9) | Every 2 or 4 weeks | ~60% | | Alirocumab (Praluent) | Monoclonal antibody (blocks PCSK9) | Every 2 or 4 weeks | ~50-60% |

Evolocumab showed a 27 percent reduction in major adverse cardiovascular events in the FOURIER trial (N=27,564). Alirocumab showed an absolute risk reduction of 1.6 percentage points in the ODYSSEY OUTCOMES trial among post-ACS patients. Inclisiran has not yet published a dedicated cardiovascular outcomes trial of equivalent scale, though the ORION-4 trial is underway and cardiovascular event data are expected by 2026. This is an evidence gap women deserve to know about before choosing between options.

Inclisiran vs. Bempedoic Acid

Bempedoic acid (Nexletol) is an oral drug that inhibits ATP citrate lyase, an enzyme upstream of HMG-CoA reductase. It lowers LDL by roughly 18 to 25 percent as monotherapy and is approved for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who need additional LDL lowering. The CLEAR Outcomes trial (2023) showed a 13 percent reduction in major adverse cardiovascular events among statin-intolerant patients. Its annual cost is substantially lower than inclisiran, and it is taken as an oral tablet daily, which some women prefer. The trade-off is a smaller LDL reduction and a small but real increase in gout risk and elevations in uric acid.

Inclisiran vs. Ezetimibe

Ezetimibe blocks cholesterol absorption in the gut. It lowers LDL by roughly 15 to 20 percent and is available as a low-cost generic. The IMPROVE-IT trial showed that adding ezetimibe to simvastatin in post-ACS patients reduced cardiovascular events by a modest but statistically significant margin. For women who need only moderate additional LDL lowering beyond a statin, ezetimibe remains the most cost-effective starting point before escalating to injectable therapy.

Inclisiran vs. High-Intensity Statins

Before reaching for inclisiran or any PCSK9-pathway drug, guidelines from the American College of Cardiology and American Heart Association recommend maximally tolerated statin therapy. Rosuvastatin 40 mg or atorvastatin 80 mg can reduce LDL by 50 to 55 percent. Inclisiran is intended as add-on therapy for women who remain above goal on statins, not as a replacement for them.

Cost Comparison: What Women Actually Pay

List prices in U.S. Drug pricing are rarely what anyone pays. The picture for inclisiran is more nuanced than the headline number suggests.

U.S. List Price vs. Net Price

The wholesale acquisition cost for inclisiran is approximately $3,490 per dose, translating to roughly $6,980 per year once the loading schedule is complete. By comparison, evolocumab (Repatha) carries a list price near $5,850 per year at the monthly-injection frequency after patient assistance, and alirocumab has a similar list price structure. Net prices after rebates and payer contracts are not publicly disclosed, but Novartis has pursued a value-based contract model with several large U.S. Health systems that ties payment to LDL outcomes.

Insurance Coverage and Prior Authorization

Medicare Part D covers inclisiran, but prior authorization requirements vary. Most commercial plans require documented failure of high-intensity statin therapy and, often, a prior trial of ezetimibe or a PCSK9 monoclonal antibody. Women with familial hypercholesterolemia may have an easier path to approval given the genetic indication. The Novartis patient assistance program, Entresto Together (expanded for Leqvio), offers copay cards that can reduce commercial-insurance out-of-pocket cost to as little as zero for eligible patients.

Clinic-Administered vs. Self-Injected: A Hidden Cost Factor

Unlike evolocumab and alirocumab, which women self-inject at home, inclisiran must be administered by a healthcare professional in a clinical setting. This is a regulatory condition of its FDA approval, not simply a manufacturer preference. That means every dose involves a clinic visit, which adds time cost, transportation cost, and potential lost wages. For women juggling work, childcare, or caregiving responsibilities, this is a real and often underdiscussed burden. On the other hand, office administration eliminates the need to store, track, and self-inject up to 26 doses per year (as required with biweekly evolocumab), which many women find appealing.

The WomanRx Practical Cost Framework for Injectable LDL-Lowering Therapy:

1. Start with maximally tolerated statin plus ezetimibe (lowest cost, good evidence).
2. If LDL remains above goal and cardiovascular risk is high, request prior authorization for a PCSK9-pathway agent.
3. If adherence is a concern (missing biweekly injections), favor inclisiran for its twice-yearly schedule despite the clinic-visit requirement.
4. If self-injection at home is strongly preferred and biweekly adherence is feasible, evolocumab or alirocumab may offer comparable or slightly greater LDL reduction with home convenience.
5. If cost is the primary barrier and LDL goal is modest, bempedoic acid or a ezetimibe-statin combination is the appropriate escalation.

Inclisiran and Women's Health: Life-Stage Considerations

Cardiovascular disease is the leading cause of death in U.S. Women, yet women have been systematically under-enrolled in lipid-lowering trials. In ORION-11, approximately 32 percent of participants were women, a proportion that mirrors, but does not improve on, the historic gender gap in cardiovascular trials. The LDL reduction observed in women in ORION-10 and ORION-11 was consistent with that in men, but sex-disaggregated subgroup data were not powered to detect differential effects. This is a genuine evidence gap.

Reproductive Years and PCOS

Women with polycystic ovary syndrome have a higher prevalence of dyslipidemia, including elevated LDL and triglycerides and low HDL. The Endocrine Society's PCOS guideline recommends aggressive lipid management in women with PCOS who have additional cardiovascular risk factors. Inclisiran has not been specifically studied in women with PCOS. For women of reproductive age with PCOS who need LDL lowering beyond statins and ezetimibe, effective contraception is required if inclisiran is used, given its teratogenic potential in animal models.

Perimenopause: The Lipid Inflection Point

LDL cholesterol rises sharply during the menopause transition. Data from the Study of Women's Health Across the Nation (SWAN) show that LDL-C increases by an average of 10 to 14 mg/dL during the perimenopause window, independent of age or body weight changes. A woman who was at LDL goal at age 45 may no longer be at goal at age 52 without any change in her diet or statin dose. This perimenopausal lipid shift is a key window for re-evaluating whether add-on therapy such as inclisiran is warranted.

Postmenopause and Established ASCVD

Postmenopausal women with established atherosclerotic cardiovascular disease or familial hypercholesterolemia are the clearest candidates for inclisiran. The twice-yearly injection schedule may be particularly well-suited to older women managing multiple medications, since it reduces pill and injection burden. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease and the updated 2022 ACC Expert Consensus Decision Pathway both support PCSK9-directed therapy in very-high-risk patients not at LDL goal despite maximally tolerated statin therapy.

Menopausal Hormone Therapy and LDL Interaction

Oral estrogen-containing hormone therapy raises triglycerides and may modestly lower LDL. Transdermal estrogen has a more neutral lipid effect. Women on hormone therapy for menopause symptoms who also carry a diagnosis of familial hypercholesterolemia or established ASCVD should have their lipid panel reviewed after any change in hormone therapy route or dose, and the treating clinician should re-evaluate whether the LDL goal is still being met before adding inclisiran.

Pregnancy, Lactation, and Contraception

Inclisiran is contraindicated during pregnancy. This is a hard stop, not a nuanced risk discussion.

Animal reproductive studies showed embryofetal toxicity at doses lower than the human clinical dose. There are no adequate human data. The FDA label states clearly that inclisiran should be discontinued prior to a planned pregnancy and that pregnancy should be excluded before starting therapy. Women of childbearing potential must use effective contraception during treatment.

Pregnancy Category and Human Data

Inclisiran has no assigned letter category under the old FDA system, which was retired in 2015. Under the current Pregnancy and Lactation Labeling Rule (PLLR), the label carries a pregnancy risk summary stating that animal data suggest risk and that human data are insufficient to establish safety. Any woman who becomes pregnant while receiving inclisiran should stop treatment immediately and consult her clinician and a maternal-fetal medicine specialist.

Lactation

There are no data on the presence of inclisiran in human breast milk, its effect on the breastfed infant, or its effect on milk production. Because LDL lowering during lactation is generally not an urgent clinical priority and the drug's effects on a nursing infant are unknown, inclisiran should not be used during breastfeeding. Statins are also generally avoided during breastfeeding; ezetimibe lacks lactation safety data as well. Women with familial hypercholesterolemia who are breastfeeding should discuss a temporary lipid-management strategy with their clinician, recognizing that a period of suboptimal LDL control during lactation carries very low absolute cardiovascular risk in most women.

Contraception Requirements

Women of reproductive age receiving inclisiran should use highly effective contraception throughout treatment. Given the six-month dosing interval, the contraceptive requirement extends for a period after the last dose, though the exact washout window for reproductive safety has not been formally defined in clinical studies. This is an area where the evidence is thin and clinician judgment must fill the gap. Long-acting reversible contraception (an IUD or subdermal implant) is one practical option that removes the risk of unplanned pregnancy without requiring daily adherence.

Who Should and Should Not Consider Inclisiran

Women Most Likely to Benefit

Women in the following situations are the strongest candidates for inclisiran:

• Confirmed heterozygous familial hypercholesterolemia with LDL above goal on maximally tolerated statin plus ezetimibe.
• Established ASCVD (prior MI, stroke, or peripheral arterial disease) with LDL persistently above 70 mg/dL.
• Documented statin intolerance (myopathy, confirmed by rechallenge) with LDL far above goal.
• Women who want or need a low-frequency injection schedule due to adherence challenges with biweekly self-injection.

Women Who Should Not Use Inclisiran

• Pregnant women or those planning pregnancy in the near term. Stop inclisiran before attempting conception.
• Breastfeeding women.
• Women with severe hepatic impairment (limited pharmacokinetic data; the drug is metabolized in the liver).
• Women whose LDL is close enough to goal that ezetimibe or optimized statin dosing would be sufficient.

A Note on Statin-Intolerant Women

Statin intolerance is more common in women than in men. A 2018 analysis in the Journal of the American Heart Association found that women were significantly more likely than men to report muscle-related side effects and to discontinue statins. For this subgroup, inclisiran is particularly relevant because it does not cause myopathy. Bempedoic acid is another option for statin-intolerant women who are not yet candidates for injectable therapy.

Clinical Administration: What to Expect

Inclisiran is given as a 284 mg subcutaneous injection, administered by a clinician, nurse, or pharmacist in a healthcare setting. The injection goes into the abdomen, upper arm, or thigh. The Day 1 and Day 90 loading doses establish the therapeutic level; every-six-month maintenance doses follow. Injection-site reactions occur in about 2.6 percent of patients, and most are mild. No pre-medication is required. The whole office visit, including wait time, should take under 30 minutes.

Because the drug is office-administered, a woman's pharmacy benefit is generally not the payer. Inclisiran billing uses medical-benefit pathways (CPT codes for the drug and the administration), which means copay structures differ from pharmacy-dispensed drugs. Women should ask their insurer whether inclisiran is covered under the medical benefit and what the prior-authorization criteria are before scheduling a first dose.

Frequently Asked Questions